Product Description
monoclonal antibody against TNF-alpha
Mechanisms of Action: TNF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Epirus
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Arthritis, Rheumatoid
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02683564 |
The UNIFORM Study | P3 |
Unknown status |
Arthritis, Rheumatoid |
2017-07-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/10/2020 |
News Article |
Infliximab Biosimilars Insight Report, 2020 - Comprehensive Insights of 35+ Companies and 45+ Marketed and Pipeline Drugs - ResearchAndMarkets.com |